Hoebe K, Jiang Z, Georgel P, Tabeta K, Janssen E, Du X, Beutler B
Department of Immunology, IMM-31, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037 USA.
Curr Pharm Des. 2006;12(32):4123-34. doi: 10.2174/138161206778743466.
The identification of the TLRs as key sensors of microbial infection has presented a series of new targets for drug development. The TLRs are linked to the most powerful inflammatory pathways in mammals. The question arises from the start: do we wish to stimulate TLR signaling in order to eradicate specific infections and/or neoplastic diseases? Or do we wish to block TLR signaling to treat inflammatory diseases? If we accept that it would be useful to modulate TLR signaling, the next step is to identify the correct molecular target(s) for the task. Perhaps it might even be possible to exercise selectivity, modulating some aspects of TLR signaling and not others. Classical and reverse genetic analyses offer insight into the possibilities that exist, and point to specific checkpoints within signaling pathways at which modulation might normally be imposed.
Toll样受体(TLR)作为微生物感染的关键传感器的发现为药物开发提供了一系列新靶点。TLR与哺乳动物中最强大的炎症信号通路相关联。从一开始就出现了这样一个问题:我们是希望刺激TLR信号传导以根除特定感染和/或肿瘤疾病?还是希望阻断TLR信号传导来治疗炎症性疾病?如果我们认为调节TLR信号传导会有用,那么下一步就是确定完成这项任务的正确分子靶点。甚至有可能实现选择性,调节TLR信号传导的某些方面而不调节其他方面。经典遗传学和反向遗传学分析有助于深入了解存在的可能性,并指出信号通路中可能通常施加调节的特定检查点。